Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI
More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1. These ...
Seeking Alpha2d
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV ...
TEV-'749 is an investigational once-monthly subcutaneous LAI of the second-generation antipsychotic olanzapine and is not approved by any regulatory authority for any use, and its safety and ...
Medscape6d
When Does Antipsychotic Sedation Peak and Fade?
Sedation peaked in the first 2 weeks in patients with acute phase schizophrenia receiving antipsychotic treatment, a study showed. About 50% of sedation cases resolved within 1 week, though 24% ...
The American Journal of Managed Care6d
Improving Treatment Adherence With LAIs for Comorbid Schizophrenia, Substance Use Disorder
Joshua Kaufman, MD, of CDPHP, discusses the significance of long-acting injectables (LAIs) in improving adherence, reducing the risk of relapse, and preventing hospitalizations.
pharmaphorum9y
Alkermes gets US nod for long-acting schizophrenia drug
a range of doses and dosing intervals and the convenience of a ready-to-use product format" that will help it carve out a position in the increasingly crowded market for LAI antipsychotics ...
Seeking Alpha2d
Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI
for the treatment of schizophrenia Olanzapine LAI (mdc-TJK / TEV-‘749) is an investigational, once-monthly, subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the ...